 |
|
| Dow | Nasdaq | About Us | Disclaimer |  |
RSS Feed |  |
Follow us on Twitter |
|
Featured Advisors |
Wednesday September 07, 2011
Geron: Advancing cancer therapies
by Tom Bishop, editor BI Research Geron (GERN) is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. We continue to rate the stock a buy. The company is advancing four anti-cancer therapies through multiple Phase II clinical trials in different cancers by targeting the enzyme telomerase. Recently, an anti-cancer compound designed to penetrate the blood-brain barrier was also added to the stable, with a Phase II trial now scheduled to begin by year end. Geron is also developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase I clinical trial in spinal cord injury. In tests on animals Geron’s stem cells have shown exciting efficacy in repairing damaged cartilage, heart muscle and even spinal cord fibers that have lost their myelin sheath. There are four Phase II cancer trials ongoing as well as the Phase I spinal cord injury trial. In addition, spending should pick up further when its GRN1005 Phase II brain cancer trial starts later this year. So Geron will have six clinical trials ongoing as it exits 2011. Five of these are scheduled to report results by Q4 2012. That is going to be an exciting time for Geron. Overall, the company has more on its plate than it can possibly handle and is in a variety of partnering discussions with larger, deeper-pocketed pharmaceutical partners. With $192 million cash, Geron can negotiate from a position of strength. So there are a lot of exciting reasons to stay at the table. In fact I think the shares at this depressed level are an intriguing Buy. Learn more about this financial newsletter at Tom Bishop's BI Research. 
|
News Flash
|
|